As recently as last summer, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As new, even more contagious variants of the virus have emerged, however, it has become […]
Read MoreYears ago, as I began my career as an investor, I read a book by Peter Lynch. Mr. Lynch had made his name, and his fortune, as the manager of Fidelity’s flagship Magellan fund in the late 70’s and ’80’s, and his incredible performance was one of the big reasons Magellan, at the time, was […]
Read MoreAs recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]
Read MoreFulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment […]
Read More
